"Corbus Pharmaceuticals' Stock Soars 300% on Positive Phase 1 Cancer Study Results"
TL;DR Summary
Corbus Pharmaceuticals' shares surged over 200% after reporting positive results from its Phase 1 study of CRB-701, a next generation nectin-4 targeting antibody drug conjugate, showing encouraging safety and efficacy in patients with nectin-4 positive tumors. The study is being conducted in China and enrolling participants with metastatic urothelial cancer and other solid tumors confirmed to have nectin-4 positive tumors.
Topics:business#cancer-study#corbus-pharmaceuticals#crb-701#healthcare#nectin-4-positive-tumors#phase-1-results
- Corbus Pharmaceuticals' Shares Triple Following Results From Phase 1 Cancer Study MarketWatch
- Why Is Corbus Pharmaceuticals (CRBP) Stock Up 300% Today? InvestorPlace
- Corbus Pharma doubles as cancer therapy shows promise in early-stage trial XM
- Corbus Pharmaceuticals Holdings, Inc. Announces Data from the First-in-Human Clinical Study of CRB-701 Marketscreener.com
- Corbus Pharmaceuticals Holdings Inc. stock falls Tuesday, underperforms market MarketWatch
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
0 min
vs 1 min read
Condensed
53%
128 → 60 words
Want the full story? Read the original article
Read on MarketWatch